Antimicrobial Sutures - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The antimicrobial sutures market size is projected to be USD 316.80 million in 2025, USD 330.54 million in 2026, and reach USD 410.27 million by 2031, growing at a CAGR of 4.40% from 2026 to 2031. This report is Segmented by Product Type (Absorbable Sutures, Non-Absorbable Sutures), by Antimicrobial Agent (Triclosan, Chlorhexidine Diacetate, and More), by Application (General Surgery, Cardiovascular Surgery, and More), by End User (Hospitals, Ambulatory Surgical Centers, and More), and by Geography (North America, Europe, Asia-Pacific, and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Antimicrobial Sutures Market Trends and Insights

Rising Surgical Procedure Volumes

Ambulatory surgical procedures per Medicare fee-for-service beneficiary rose 3.5% in 2024. The supplied research expects total ambulatory surgical center volume to rise 21% between 2024 and 2034, reaching 44 million procedures each year. This shift expands the serviceable base for the Antimicrobial sutures market because infection control in outpatient facilities relies heavily on product selection. Hospitals can use broader environmental controls that are less available in many ambulatory settings. The addition of 573 procedures to the 2026 ASC Covered Procedures List broadened the range of cases that can move into these settings. Cardiac catheter ablation is among the higher-acuity procedures included in that expansion, which can increase antimicrobial suture use per case.

Increasing Surgical Site Infection Prevention Requirements

Surgical site infections account for more than 20% of health care-associated infections in the United States and affect an estimated 300,000 patients each year. The CDC guidance updated in April 2024 and the WHO 29-point prevention framework remain important references for hospitals addressing infection control obligations. Surgical site infection-related hospitalizations added USD 30,689 in hospital costs per case in a 2025 study. The cost burden makes prevention relevant to hospital financial management as well as clinical quality programs. This setting supports inclusion of antimicrobial sutures in formularies and standard suture selection protocols. The Antimicrobial sutures market, therefore, benefits from quality reporting and value-based purchasing, which create institutional accountability.

Competition from Staplers, Tissue Adhesives, and Wound-Closure Devices

Mechanical staplers and tissue adhesives have improved and compete with sutures in more laparoscopic, robotic, and dermatological procedures. The supplied forecast expects adult ambulatory surgical utilization to grow 23% during the current decade. It also expects cardiovascular ablations and orthopedic reconstruction to grow 26% in ambulatory surgical centers. These procedures increasingly use staple-based or device-based closure methods. Minimally invasive techniques can reduce the number of tissue layers that require suturing. This reduces suture use per procedure and limits premium capture for the Antimicrobial sutures market.

Other drivers and restraints analyzed in the detailed report include:

• Guideline and Clinical Evidence Support for Antimicrobial Sutures
• Smart, Bioresorbable, and Drug-Eluting Suture Innovation
• Environmental and Regulatory Scrutiny of Triclosan and Nanoparticles

Segment Analysis

Absorbable sutures held 62.89% of 2025 revenue and are forecast to grow at a 5.37% CAGR through 2031. This combined position reflects their fit in soft-tissue and gastrointestinal procedures. Absorbable materials avoid permanent foreign-body retention after healing. This feature is relevant in contaminated and immunocompromised wound environments. It can also reduce the baseline inflammatory response associated with retained materials. The Antimicrobial sutures market size for absorbable formats is supported by their role in procedures where removal is not practical.

Polyglactin 910 and poliglecaprone-25 are the leading polymer substrates in this segment. Their use pairs bioresorbability with antimicrobial coating options. Ethicon received clearance in 2026 for MONOCRYL Plus Antibacterial Poliglecaprone-25 and Coated VICRYL Plus Antibacterial Polyglactin 910. The supplied research notes that the latter device underwent a 268-day review, reflecting post-market surveillance expectations for updated devices. Non-absorbable sutures continue to serve cardiovascular, ophthalmic, and vascular anastomosis procedures. Polypropylene and nylon formats with silver-ion or chlorhexidine coatings have a role where long-term tensile integrity is required. Their use in orthopedic and cardiac procedures reflects the clinical consequences of infection around a permanent suture.

Triclosan captured 68.17% of 2025 revenue, supported by its early entry, clinical trial base, and guideline recognition. Chlorhexidine diacetate is forecast to grow at a 5.89% CAGR through 2031, the highest rate among antimicrobial agents. The Antimicrobial sutures industry is shifting attention toward alternatives with a different regulatory profile. A 2025 trial followed 468 laparoscopic patients for 12 months and reported numerical surgical site infection reduction with chlorhexidine-coated sutures. A periodontal comparison also reported lower colony-forming units with chlorhexidine-coated sutures than with triclosan-coated sutures, at 0.011 × 10⁶ versus 4.3 × 10⁶.

B. Braun's Novosyn CHD uses a polyglactin 910 suture with chlorhexidine diacetate coating. The product is active in the Middle East and Africa markets and is available across Europe. It shows how antimicrobial agent selection can differentiate products as buyers consider triclosan exposure. Silver-ion and silver-nanoparticle coatings remain an emerging area in oral surgery and orthopedic applications. An in vitro study reported activity against antibiotic-resistant strains, including Pseudomonas aeruginosa. Chitosan-based coatings, antibiotic-eluting matrices, and stimulus-responsive constructs remain at research or early clinical stages. Their progress will depend on biocompatibility evaluation and regulatory review before commercial-scale adoption.

Complete Report Scope:

• By Product Type
  • Absorbable Sutures
  • Non-Absorbable Sutures
• By Antimicrobial Agent
  • Triclosan
  • Chlorhexidine Diacetate
  • Silver-Ion and Silver-Nanoparticle Coatings
  • Chitosan-Based Coatings
  • Others
• By Material
  • Synthetic Polymers
  • Natural Materials
  • Bioresorbable and Bioactive Materials
• By Application
  • General Surgery
  • Cardiovascular Surgery
  • Orthopedic Surgery
  • Gynecological and Obstetric Surgery
  • Colorectal Surgery
  • Other Surgical Applications
• By End User
  • Hospitals
  • Ambulatory Surgical Centers
  • Specialty Clinics
  • Academic and Research Institutions
  • Other End Users
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held 41.21% of 2025 revenue in the Antimicrobial sutures market. The region benefits from a system in which surgical site infection rates are measured, reported, and connected to hospital performance requirements. In the United States, the National Healthcare Safety Network provides procedure-specific infection benchmarks for hospitals and surgeons. These benchmarks create direct accountability for infection prevention and suture selection. Canada and Mexico account for smaller regional shares. Mexico has higher growth potential as private surgical capacity expands in metropolitan areas.

Europe is the second-largest regional market, shaped by clinical documentation and post-market evidence requirements under the EU Medical Device Regulation. Germany, the United Kingdom, and France are the largest country markets in the region. Hospital group formularies support institutional purchasing in those countries. Spain and Italy are seeing faster adoption as private hospital capacity and infection-control programs expand. A 2025 study at Gemelli University Hospital in Rome reported that surgical site infection prevalence fell from 2.50% in 2023 to 1.40% in 2024. It linked that reduction to EUR 31.6 million in avoided direct health care costs, equivalent to USD 33 million.

Asia-Pacific is forecast to grow at a 5.88% CAGR through 2031, the fastest regional rate. China, India, Japan, South Korea, and Australia each contribute different demand conditions. India has a domestic supply base that includes Healthium Medtech, Futura Surgicare, Lotus Surgicals, and Meril Life Sciences. This supply base expands access in public hospitals that place a strong emphasis on price. Japan prioritizes guideline-compliant infection prevention, while South Korea's Samyang Holdings has a regional position in absorbable formats.

List of Companies Covered in this Report:

• Advanced MedTech Solutions Pvt. Ltd.
• Assut Europe S.p.A.
• B. Braun
• Boz Medical
• DemeTECH
• Dolphin Sutures
• Genesis MedTech Group
• Healthium Medtech Limited
• Internacional Farmacéutica, S.A. de C.V.
• Johnson & Johnson
• Katsan Medical Devices
• Lotus Surgicals Pvt. Ltd.
• Meril Life Science
• Peters Surgical
• Riverpoint Medical
• Samyang Holdings Corporation
• SMI AG
• Suture Planet
• Sutures India Pvt. Ltd
• Unilene

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support